Skip to content
Synopulse
  • The Brief
    • Quick
    • In Depth
    • Editor’s Pick
  • Reports
    • The beats
      • Catalyst
      • AccessWatch
      • DealPulse Signal
      • DealPulse Report
    • Analysis
      • The Throughline
      • The Top Line
      • The Forecast
    • Coverage
      • ShowFloor
      • The Arena
  • The Pulse
    • NeuroPulse
    • OrphanPulse
  • Topics
    • By subject
      • Deals
      • Regulatory
      • Market Access
      • Pricing & Reimbursement
      • Legal & Policy
    • By technology
      • Antibody
      • Cell & Gene Tx
      • Drug conjugates
      • AI/ML
      • Digital Health
      • Radiopharma
    • By therapy area
      • Neurology
      • Oncology
      • Rare Diseases
      • Cardio-Metabolic
      • Immunology & Inflammation
      • Orthopaedics
Italy Ran an Innovation Test for Eight Years.
Italy Ran an Innovation Test for Eight Years.
Athithi Verma July 28, 2026
Italy graded new medicines full, conditional or not innovative for eight years. The 2025 reform abolished the middle grade, because almost nothing ever graduated.
A New Antibiotic Reached a Middle-Income Country Six Months After the US
A New Antibiotic Reached a Middle-Income Country Six Months After the US
Argentina Just Made One Agency the Buyer for Five National Hospitals
Argentina Just Made One Agency the Buyer for Five National Hospitals
Britain Thought It Had an Opt-Out. Washington Reads the Deal Differently.
Britain Thought It Had an Opt-Out. Washington Reads the Deal Differently.
Wet AMDโ€™s Problem Was Never the Drug. It Was the Injections.
Wet AMDโ€™s Problem Was Never the Drug. It Was the Injections.
ADCs Graduated From Salvage to First Line, Twice in a Week
ADCs Graduated From Salvage to First Line, Twice in a Week

Editor’s Pick

Britain Thought It Had an Opt-Out. Washington Reads the Deal Differently.

Britain Thought It Had an Opt-Out. Washington Reads the Deal Differently.

One Trial Miss Cut AstraZeneca's Cushion Above $80bn to $800m

One Trial Miss Cut AstraZenecaโ€™s Cushion Above $80bn to $800m

White House and London Clinch Drug-Pricing Deal With 25% UK Price Lift

White House and London Clinch Drug-Pricing Deal With 25% UK Price Lift

NeuroPulse


NeuroPulse Wk 30: Three Orexin Programmes in Two Weeks

NeuroPulse Wk 30: Three Orexin Programmes in Two Weeks

NeuroPulse Wk 29 First Brain Link Shares Movement Between Two People

NeuroPulse Wk 29: First Brain Link Shares Movement Between Two People

OrphanPulse


OrphanPulse Wk 30: CHMP Backs a Drug It Refused Twice

OrphanPulse Wk 30: CHMP Backs a Drug It Refused Twice

OrphanPulse Wk 29 Ionis Takes SMA-Proven Antisense Into Dravet Syndrome

OrphanPulse Wk 29: Ionis Takes SMA-Proven Antisense Into Dravet Syndrome

DealPulse Signal


DealPulse Signal Wk 30: Three Billion-Dollar Deals, No Drugs

DealPulse Signal Wk 30: Three Billion-Dollar Deals, No Drugs

DealPulse Signal Wk 29 The Biggest Deal of the Week Was a Bare Line

DealPulse Signal Wk 29: The Biggest Deal of the Week Was a Bare Line

DealPulse Report


DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

The Beats


DealPulse Signal Wk 30: Three Billion-Dollar Deals, No Drugs

DealPulse Signal Wk 30: Three Billion-Dollar Deals, No Drugs

DealPulse Signal Wk 29 The Biggest Deal of the Week Was a Bare Line

DealPulse Signal Wk 29: The Biggest Deal of the Week Was a Bare Line

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

Analysis


Reshaping Pharma by 2027

7 Market Access Trends Reshaping Pharmaย by 2027

The Biologics Patent Cliff: Inside Pharma's 2026-2029 Reckoning

The Biologics Patent Cliff: Inside Pharma’s 2026-2029 Reckoning

Coverage


The ADC Decade Accelerates What to Watch at ASCO 2026

The ADC Decade Accelerates: What to Watch at ASCO 2026

The Briefs

Italy Ran an Innovation Test for Eight Years.

Italy Ran an Innovation Test for Eight Years.

Athithi Verma July 28, 2026
A New Antibiotic Reached a Middle-Income Country Six Months After the US

A New Antibiotic Reached a Middle-Income Country Six Months After the US

Athithi Verma July 28, 2026
Argentina Just Made One Agency the Buyer for Five National Hospitals

Argentina Just Made One Agency the Buyer for Five National Hospitals

Athithi Verma July 28, 2026
Britain Thought It Had an Opt-Out. Washington Reads the Deal Differently.

Britain Thought It Had an Opt-Out. Washington Reads the Deal Differently.

Athithi Verma July 28, 2026
Wet AMDโ€™s Problem Was Never the Drug. It Was the Injections.

Wet AMDโ€™s Problem Was Never the Drug. It Was the Injections.

Athithi Verma July 27, 2026
ADCs Graduated From Salvage to First Line, Twice in a Week

ADCs Graduated From Salvage to First Line, Twice in a Week

Athithi Verma July 27, 2026
Read More
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress